Σελίδα 1 από 44 Αποτελέσματα
FIELD OF THE DISCLOSURE
The present disclosure relates to the field of medicinal chemistry. More particularly, it relates to polyunsaturated fatty acid monoglyceride compounds and derivatives thereof. It also relates to compositions which comprise such compounds. There is also provided a method for
TECHNICAL FIELD
The present disclosure relates to lipid compounds of the general formula (I):
##STR00001## wherein R.sub.1 is a C.sub.10-C.sub.22 alkyl group, a C.sub.10-C.sub.22 alkenyl group having 1-6 double bonds, or a C.sub.10-C.sub.22 alkynyl group having 1-6 triple bonds; R.sub.2 and R.sub.3
FIELD OF THE DISCLOSURE
The present disclosure relates to the field of medicinal chemistry. More particularly, it relates to polyunsaturated fatty acid monoglyceride compounds and derivatives thereof. It also relates to compositions which comprise such compounds. There is also provided a method for
BACKGROUND OF THE INVENTION
This application is in the area of methods and compositions for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases.
Adhesion of leukocytes to the endothelium represents a fundamental, early event in a wide variety of inflammatory
Adhesion of leukocytes to the endothelium represents a fundamental, early event in a wide variety of inflammatory conditions, including atherosclerosis, autoimmune disorders and bacterial and viral infections. Leukocyte recruitment to the endothelium is started when inducible adhesion molecule
BACKGROUND OF THE INVENTION
This application is in the area of methods and compositions for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases.
Adhesion of leukocytes to the endothelium represents a fundamental, early event in a wide variety of inflammatory
This application is in the area of methods and compositions for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases.
Adhesion of leukocytes to the endothelium represents a fundamental, early event in a wide variety of inflammatory conditions, including
This application is in the area of methods and compositions for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases.
Adhesion of leukocytes to the endothelium represents a fundamental, early event in a wide variety of inflammatory conditions, including
BACKGROUND OF THE INVENTION
This application is in the area of methods and compositions for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases.
Adhesion of leukocytes to the endothelium represents a fundamental, early event in a wide variety of inflammatory
FIELD OF THE DISCLOSURE
This disclosure relates to previously unknown compounds, compositions, and methods of use for the prevention and treatment of inflammatory, degenerative, and neurodegenerative diseases, including related conditions or disorders. More specifically, this disclosure relates to
FIELD OF THE INVENTION
This invention generally relates to the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. The
FIELD OF THE INVENTION
The invention relates generally to the fields of natural products, inflammation, pathology, and medicine. More particularly, the invention relates to Specialized Proresolving Mediators (SPMs) and SPM precursors obtained from natural sources, and their use in nutritional
This application is a 371 of PCT/AU95/00677 filed Oct. 13, 1995.
The present invention relates to new polyunsaturated fatty acids having antimalarial activity and/or neutrophil stimulatory activity. The present invention further relates to a group of modified polyunsaturated fatty acids which have
The present invention relates to new polyunsaturated fatty acids having antimalarial activity and/or neutrophil stimulatory activity. In addition, certain of the new polyunsaturated fatty acids depress cytokine activity.
Over half of the world's population is at risk from malaria, with about 500
This application is a U.S. national stage of PCT/EP2017/066002 filed on 28 Jun. 2017, which claims priority to and the benefit of Italian Application No. 102016000067621 filed on 29 Jun. 2016, the contents of which are incorporated herein by reference in their entireties.
TECHNICAL FIELD OF